Other Events ·
Arcus Biosciences reports preliminary $694M cash and marketable securities balance as of September 30
RCUSArcus Biosciences, Inc.
Arcus Biosciences estimates it held approximately $694.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026. This figure is preliminary, unaudited, and subject to adjustment upon completion of financial closing procedures and management reviews. The company notes this estimate does not constitute a comprehensive statement of its financial results or condition for the period. Arcus Biosciences operates in the biotechnology industry, focusing on the discovery and development of immunotherapies.